XML 21 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid In Capital
Accumulated Deficit
Net Parent Company Investment
Accumulated Other Comprehensive Income (Loss)
Beginning Balance at Dec. 31, 2021 $ 1,451,377 $ 0 $ 0 $ 0 $ 1,494,157 $ (42,780)
Net loss (63,881) 0 0 (47,532) (16,349) 0
Net transactions with Zimmer Biomet Holdings Inc (70,430) 0 0 0 (70,430) 0
Net considerations paid to Zimmer Biomet Holdings, Inc. in connection with distribution (540,567) 0 0 0 (540,567) 0
Reclassification of net parent company investment to additional paid-in capital 0 261 866,550 0 (866,811) 0
Stock plan activity 190 1 189 0 0 0
Share-based compensation expense 30,289 0 30,289 0 0 0
Other comprehensive (loss) income (48,374) 0 0 0 0 (48,374)
Ending Balance at Dec. 31, 2022 758,604 262 897,028 (47,532) 0 (91,154)
Net loss (393,282) 0 0 (393,282)   0
Stock plan activity (1,043) 9 (1,052) 0 0 0
Share-based compensation expense 27,020 0 27,020 0 0 0
Other comprehensive (loss) income 18,194 0 0 0 0 18,194
Ending Balance at Dec. 31, 2023 409,493 271 922,996 (440,814) 0 (72,960)
Net loss (25,825) 0 0 (25,825)   0
Stock plan activity (952) 6 (958) 0 0 0
Share-based compensation expense 16,592,000 0 16,592,000 0 0 0
Other comprehensive (loss) income (17,601) 0 0 0 0 (17,601)
Ending Balance at Dec. 31, 2024 $ 381,707 $ 277 $ 938,630 $ (466,639) $ 0 $ (90,561)